Relief of benign essential blepharospasm and ? memory loss by cyproheptadine.
These results in a small group of patients seem quite clear for the benefit of cyproheptadine in patients with BEB, especially where botulinum A injections fail, are too expensive, or are refused. The apparent memory improvement requires further study. A search for more effective serotonin antagonists without the anticholinergic and antihistaminic side effects of cyproheptadine is needed and is in process.